Saniona AB (publ) (FRA:30S)

Market Cap	273.04M
Revenue (ttm)	67.22M
Net Income (ttm)	51.87M
Shares Out	n/a
EPS (ttm)	0.41
PE Ratio	5.26
Forward PE	9.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	106
Open	1.850
Previous Close	1.842
Day's Range	1.850 - 1.850
52-Week Range	0.480 - 2.030
Beta	n/a
RSI	60.19
Earnings Date	Nov 27, 2025

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Pharmaceutical Preparations
• Founded: 2011
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 30S

Financial Performance

Financial numbers in SEK